+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Role of thrombophilia in adverse obstetric outcomes and their prevention using antithrombotic therapy

Role of thrombophilia in adverse obstetric outcomes and their prevention using antithrombotic therapy

Seminars in Thrombosis and Hemostasis 35(7): 630-643

A series of case-control studies in the last decade have shown the role of inherited thrombophilia in the occurrence of adverse obstetric outcomes. In small series of cases, it has been proven that rare inherited causes of thrombophilia such as natural anticoagulant deficiencies can be associated with fetal losses. The confirmed presence of antiphospholipid antibodies in plasma, representing an acquired thrombophilic condition, is also an established cause of fetal losses, although other studies with a smaller sample size have found an association with other obstetric complications, namely preeclampsia, fetal growth restriction, and abruption placentae. Case-control studies have been performed regarding the potential association between unexplained fetal losses and mild hyperhomocysteinemia. Although case-control and prospective studies are also available regarding hyperhomocysteinemia and other gestational vascular complications, published data are conflicting. Intervention studies have been performed to prevent adverse obstetric outcomes in women with inherited or acquired thrombophilia and previous adverse outcomes. There is much debate in the literature regarding the need for treatment of women with thrombophilia during pregnancy. Although in most cases these are not randomized controlled trials, all studies found significantly better outcomes in treated pregnancies compared with those of untreated pregnancies.

Accession: 055614834

Download citation: RISBibTeXText

PMID: 20013530

DOI: 10.1055/s-0029-1242717

Related references

Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. Journal of Obstetrics and Gynaecology Canada 29(10): 787-793, 2007

The role of dalteparin and ASA for preventing adverse obstetric outcomes in women with inherited thrombophilia. American Journal of Obstetrics & Gynecology 189(6 Supplement): S87, 2003

VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl): E691s-E736s, 2012

Preventing adverse obstetric outcomes in women with genetic thrombophilia. Fertility & Sterility 78(2): 371-375, 2002

Genetic risk assessment of thrombophilia in patients with adverse obstetric outcomes. Plos One 14(2): E0211114, 2019

Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. American Journal of Obstetrics and Gynecology 197(5): 457.E1-21, 2007

Antithrombotic Therapy and Pregnancy: Consensus Report and Recommendations for Prevention and Treatment of Venous Thromboembolism and Adverse Pregnancy Outcomes. Obstetric Anesthesia Digest 28(3): 137-138, 2008

ABC of antithrombotic therapy: Antithrombotic therapy in special circumstances. II-In children, thrombophilia, and miscellaneous conditions. Bmj 326(7380): 93-96, 2003

Effects of anticoagulant therapy on pregnancy outcomes in patients with thrombophilia and previous poor obstetric history. Blood Coagulation and Fibrinolysis 26(3): 267-273, 2015

The role of thrombophilia testing in women with adverse pregnancy outcomes. Obstetrician & Gynaecologist 19(2): 163-172, 2017

Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy. Journal of Clinical Investigation 126(8): 2933-2940, 2017

Inherited thrombophilia in women with poor aPL-related obstetric history: prevalence and outcomes. Survey of 208 cases from the European Registry on Obstetric Antiphospholipid Syndrome cohort. American Journal of Reproductive Immunology 76(2): 164-171, 2017

HIV infection or HAART therapy: what is the cause of adverse obstetric outcomes. Archives of Gynecology and Obstetrics 296(3): 607-608, 2017

Preventing adverse obstetric outcome in women with thrombophilia. Annales de Medecine Interne 154(5-6): 366-369, 2004

Conceptualising the prevention of adverse obstetric outcomes among immigrants using the 'three delays' framework in a high-income context. Social Science & Medicine 75(11): 2028-2036, 2012